Insight Molecular Diagnostics Inc. IMDX
2.49 USD 0.00 (+0.00%)
At closeNov 6, 2026, 4:00 PM EST
2.49 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
Day range unavailable
2.35 52-week range 8.51
- YTD
- -66.80%
- 1 year
- -61.69%
News
globenewswire.com iMDx to Release Third Quarter Results on November 16, 2026 NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the…
benzinga.com iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale As previously reported, Insight Molecular Diagnostics Inc. (the "Company" or "iMDx") entered into an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and
benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8 LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
benzinga.com Transcript: Insight Molecular Q2 2026 Earnings Conference Call Insight Molecular (NASDAQ:IMDX) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings…- benzinga.com Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo,…
benzinga.com CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 23.33 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Insight Molecular Q1 2026 Earnings Call Transcript - benzinga.com Insight Molecular Q1 Adj. EPS $(0.28) Misses $(0.26) Estimate, Sales $32.000K Miss $300.000K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 47.37 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Alpha Buying: Insider Conviction in High-Risk Biotech - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results.Submitted GraftAssureDx™ for kidney…
benzinga.com Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of…- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Lake Street Maintains Buy on Insight Molecular, Raises Price Target to $12 Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the price target from $8 to $12.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and…
benzinga.com Insight Molecular Outlines Commercial Gains, FDA De Novo Submission Plans For GraftAssureDx In 2026 GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at- benzinga.com Needham Maintains Buy on Insight Molecular, Raises Price Target to $9 Needham analyst Mike Matson maintains Insight Molecular (NASDAQ:IMDX) with a Buy and raises the price target from $4.25 to $9.
- benzinga.com Insight Molecular Q3 EPS $(0.34) Misses $(0.21) Estimate, Sales $139.000K Miss $284.000K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.21) by 60.38 percent. This is a 17.07 percent increase over losses of…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com A Look at Insight Molecular's Upcoming Earnings Report
- benzinga.com Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Monitoring High-Risk Kidney Transplant Patient American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to…
benzinga.com Insight Molecular Launches 5,000-Patient Registry To Advance Kidney Transplant Rejection Test Insight Molecular Diagnostics, Inc. (NASDAQ:IMDX), ("iMDx"), today announced a positive strategic update and novel registry that will serve to gather real-world data on patient experiences and…- benzinga.com Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026NASHVILLE,…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Needham Reiterates Buy on Insight Molecular, Maintains $4.25 Price Target Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:IMDX) with a Buy and maintains $4.25 price target.
- benzinga.com Insight Molecular Q2 EPS $(0.30) Misses $(0.23) Estimate, Sales $518.000K Beat $292.000K Estimate Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.23) by 30.43 percent. This is a 16.67 percent increase over losses of…
benzinga.com Earnings Scheduled For August 11, 2025 
benzinga.com Exploring Insight Molecular's Earnings Expectations - benzinga.com Insight Molecular Diagnostics To Present Two Oral Abstracts At World Transplant Congress iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com iMDx Reports Results From Study Evaluating Flagship Test Kit Technology In Head-to-head Comparison With Another Commercially Available Test Kit. Study indicates iMDx flagship technology's equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx's digital PCR-based test kits with NGS kits shows consistent…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session